ESMO--EANM Advanced Course on Diagnostic and Therapeutic Applications of Nuclear Medicine in Oncology, 22-23 May 2024, Essen, Germany
Online application is open until 3 April 2024
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Connect with fellow researchers and forge collaborations that can lead to new discoveries and advancements
Get global visibility for your new research in GI tumours, from 26 to 29 June 2024, in Munich, Germany.
A unique opportunity to have your questions answered by world-renowned experts in breast cancer
Registration for the ESMO Academy 2024 is now open. Get your update on the key topics in medical oncology.
The living guideline is directly linked to ESMO-MCBS scores and references, easily accessible on desktop and mobile devices
Listen to international experts treating real-world cases and get first-hand insights applicable to your daily practice.
Abstracts, slides and webcasts now available
Present your latest cancer research to the widest possible audience in our live, online sessions
Online application is open until 3 April 2024
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Evidence for efficacy is based on the results from the PhALLCON study
Findings from a phase Ib study
New indication concerns the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
Findings from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
The EHDS can unlock the potential of health data for cancer research, whilst delivering on the needs of patients with cancer
Findings from a protocol-specified interim analysis of the NATALEE study
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
Expanding the guide’s availability in more languages
Evidence for efficacy is based on the results from the PhALLCON study
Findings from a phase Ib study
New indication concerns the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer
Findings from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Findings from a protocol-specified interim analysis of the NATALEE study
New indication concerns the treatment of patients with advanced RET fusion-positive solid tumours
Efficacy for evidence is based on the results from the Study BGB-3111-212
Findings from a deep metagenomic sequencing of baseline foecal samples from patients included in the CA209-538 study
Findings from the studies with dual targeting next generation engineered CAR T-cells
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care
Experts predict death rates from all cancers for the EU and UK for 2024
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society
As the ESMO Congress 2023 opens its doors in Madrid this week, ESMO calls all EU member states to act on the recently adopted final text of the EU Consumer Credits Directive by following their European neighbours Spain and France and guaranteeing cancer survivors seeking financial credit the so-called right to be forgotten after a period of five years following the end of their treatment
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
The European Society for Medical Oncology (ESMO) has announced today that the 2024 ESMO TAT Honorary Award is bestowed to Funda Meric-Bernstam
ESMO is pleased to announce the renewal of its status as non-State actor in official relations with the World Health Organization - a privilege granted to non-governmental organisations, which recognises ESMO’s sustained and systematic engagement in the interest of the WHO
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
As the world observes Universal Health Coverage Day, ESMO anticipates the results of the latest study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines, highlighting a worrying stall over the last five years
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
ctDNA offers immense possibilities for improving the management of early-stage lung cancer and the area is primed for new trials to test this approach in the context of minimal residual disease
Personalised proteogenomics has the power to transform the identification, staging and management of NSCLC in never smokers
Analyses of FLAURA2, MARIPOSA and MARIPOSA-2 trials provide further guidance on treatment choices for advanced lung cancer, but questions remain about optimal sequencing
Two studies add further evidence of the advantages of this route for delivering immune checkpoint inhibitors for patients and healthcare sustainability
Efficacy for savolitinib in patients with MET exon 14 alterations is in line with that for other MET tyrosine kinase inhibitors, but safety profile is different
Despite recent progress, lung cancer remains deadly and difficult to treat — and preventable, to a much greater extent with the right actions to improve the quality of the air we breathe
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.